Skip to main content

Military Health System

Important Notice about Pharmacy Operations

Change Healthcare Cyberattack Impact on MHS Pharmacy Operations. Read the statement to learn more. 

Skip subpage navigation

DOD P&T Committee: 2023 Meetings

Nov. 1-2, 2023

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: July 19, 2023
  • Pre-Proposal Teleconference: Aug. 9, 2023 at 1 p.m. CT
  • UF BPA & UF ADP Class Quotes Due: Sept. 8, 2023 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • MIGRAINE AGENTS - CGRP CLUSTER HEADACHE:
    • Emgality 100mg/ml
  • MIGRAINE AGENTS - CGRP PREVENTATIVE:
    • Aimovig
    • Ajovy
    • Emgality 120mg/ml
  • NEUROLOGICAL AGENTS MISCELLANEOUS - MOVEMENT DISORDERS:
    • Austedo
    • Austedo XR
    • Ingrezza
  • Airsupra
  • Brenzavvy
  • Cyltezo
  • Hadlima
  • Hulio + unbranded biologic
  • Hyrimoz + unbranded biologic
  • Lyuzeh
  • Lodoco
  • Ngenla
  • Olpruva
  • Opvee
  • Sohonos
  • Suflave
  • Vanflyta
  • Xdemvy
  • Yuflyma
  • Yusimry

 

 

 


Aug. 2-3, 2023

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: April 20, 2023
  • Pre-Proposal Teleconference: May 10, 2023 at 1 p.m. CT
  • UF BPA & UF ADP Class Quotes Due: June 15, 2023 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - PROSTATE CANCER AGENTS:
    • Camcevi
    • Eligard
    • Firmagon
    • Leuprolide Depot 22.5mg
    • Lupron Depot 7.5mg, 22.5mg, 30mg, and 45mg
    • Orgovyx
  • LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - CENTRAL PRECOCIOUS PUBERTY AGENTS:
    • Fensolvi
    • Lupron Depot-Ped
  • LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - ENDOMETRIOSIS/FIBROIDS AGENTS:
    • Lupron Depot 3.75mg & 11.25mg
    • Myfembree
    • Oriahnn
    • Orilissa
  • WHITE BLOOD CELL STIMULANTS - FILGRASTIM:
    • Granix
    • Neupogen
    • Nivestym
    • Releuko
    • Zarxio
  • WHITE BLOOD CELL STIMULANTS - PEGFILGRASTIM:
    • Fulphila
    • Fylnetra
    • Neulasta 
    • Neulasta Onpro
    • Nyvepria
    • Stimufend
    • Udenyca
    • Ziextenzo
  • Atropine Sulfate 1% Opt
  • Austedo XR
  • Cuvrior
  • Inpefa
  • Joenja
  • Liqrev
  • Lumryz
  • Miebo Opt
  • Skyclarys
  • Sogroya
  • Veozah
  • Vowst
  • Zavzpret
  • Zolpidem Tartrate 7.5mg Cap

 

 

 


May 3-4, 2023

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: Jan. 27, 2023
  • Pre-Proposal Teleconference: Feb. 1, 2023 at 1 p.m. CT
  • UF BPA & UF ADP Class Quotes Due: March 20, 2023 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • ANTILIPIDEMICS-1 - PCSK9:
    • Praluent
    • Repatha
  • OPHTHALMIC - DRY EYE:
    • Cequa
    • Eysuvis
    • Restasis
    • Tyrvaya
    • Xiidra
    • Verkazia
  • Amjevita
  • Altuviiio
  • Atorvaliq
  • Daybue
  • Filspari
  • Jaypirca
  • Konvomep
  • Krazati 
  • Orserdu
  • Pradaxa Pellets
  • Rezvoglar
  • Stimufend
  • Tezspire

 

 

 


Feb. 8-9, 2023

Uniform Formulary Request for Quote Information (Class Nephrology Misc.)

  • UF BPA & UF ADP RFQ Documents Posted: Dec. 2, 2022
  • Pre-Proposal Teleconference: Dec. 7, 2022 at 1 p.m. CT
  • UF BPA & UF ADP Class Quotes Due: Jan. 20, 2023 at 12 p.m. CT

Uniform Formulary Request for Quote Information (Class Androgens Anabolic Steroids and Sleep Disorders)

  • UF BPA & UF ADP RFQ Documents Posted: Oct. 24, 2022
  • Pre-Proposal Teleconference: Nov. 9, 2022 at 1 p.m. CT
  • UF BPA & UF ADP Class Quotes Due: Dec. 14, 2022 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • ANDROGENS-ANABOLIC STEROIDS - TESTOSTERONE REPLACEMENT THERAPIES:
    • Androderm
    • Jatenzo
    • Kyzatrex 
    • Methitest 
    • Natesto
    • Testim
    • Testred
    • Tlando
    • Xyosted
  • SLEEP DISORDERS - DUAL OREXIN RECEPTOR ANTAGONISTS:
    • Belsomra
    • Dayvigo
    • Quviviq
  • NEPHROLOGY AGENTS MISCELLANEOUS – NA:
    • Tarpeyo
  • Auvelity
  • Basaglar Tempo Pen
  • Ermeza
  • Furoscix
  • Fylnetra
  • Humalog Tempo Pen
  • Leuprolide Depot
  • Lytgobi
  • Lyumjev Tempo Pen
  • Noxafil
  • Relyvrio
  • Rezlidhia
  • Xelstrym

 


Last Updated: February 02, 2024
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Sign up on GovDelivery